Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The only drugs currently approved for the treatment of Alzheimer's Disease (AD) are four acetylcholinesterase inhibitors and the NMDA antagonist memantine. Apart from these drugs, which have minimal to no clinical benefit, the 40‐year search for effective therapeutics to treat AD has resulted in a clinical failure rate of 100% not only for compounds that prevent brain amyloid deposition or remove existing amyloid plaques but also those acting by a variety of other putative disease‐associated mechanisms. This indicates that the preclinical data generated from current AD targets to support the selection, optimization, and translation of new chemical entities (NCEs) and biologics to clinical trials is seriously compromised. While many of these failures reflect flawed hypotheses or a lack of adequate characterization of the preclinical pharmacodynamic and pharmacokinetic (PD/PK) properties of lead NCEs—including their bioavailability and toxicity—the conceptualization, validation, and interrogation of the current animal models of AD represent key limitations. The overwhelming majority of these AD models are transgenic, based on aspects of the amyloid hypothesis and the genetics of the familial form of the disease. As a result, these generally lack construct and predictive validity for the sporadic form of the human disease. The 170 or so transgenic models, perhaps the largest number ever focused on a single disease, use rodents, mainly mice, and in addition to amyloid also address aspects of tau causality with more complex multigene models including other presumed causative factors together with amyloid. This overview discusses the current animal models of AD in the context of both the controversies surrounding the causative role of amyloid in the disease and the need to develop validated models of cognitive function/dysfunction that more appropriately reflect the phenotype(s) of human aged‐related dementias. © 2019 by John Wiley & Sons, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“…incomplete understanding of the complexity and mechanism(s) of AD causality that resulted in an overarching focus on the amyloid hypothesis of AD (Hardy & Higgins, 1992), despite clinical studies with a 100% failure rate that question its relevance, to the almost total exclusion of other…”
BackgroundImproving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · cited 1×
“Initial efforts in the latter half of the 20 th century to find therapeutics for AD focused on the cholinergic hypothesis (Bartus, Dean, Beer, & Lippa, 1982; Terry & Buccafusco, 2003), which was based on the association between cholinergic dysfunction, including degeneration of cortically projecting…”
BackgroundMorris water maze: procedures for assessing spatial and related forms of learning and memory
Vorhees, C. V., & Williams, M. T. (2006) · Nature Protocols · doi:10.1038/nprot.2006.116 · Cited by 4,629
Self-citationCorrelative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data
Ennaceur, A., & Delacour, J. (1988) · Behavioural Brain Research · doi:10.1016/0166-4328(88)90157-x · Cited by 3,223
Redefine statistical significance
Benjamin, D. J., Berger, J. O., Johannesson, M., Nosek, B. A., Wagenmakers, E.-J., Berk, R., Bollen, K. A., Brembs, B., Brown, L., Camerer, C., et al. (2017) · Nature Human Behaviour · doi:10.1038/s41562-017-0189-z · Cited by 2,772
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516 · cited 2×
“These range in complexity from the PDAPP mouse that expresses a single gene mutation, the human familial Indiana APP V717F (Games et al., 1995), to the recently developed triple transgenic mouse, App KO/APOE4/ Trem2*R47, which carries a humanized APOE4 gene, the p.R47H mutation knocked into mouse…”
BackgroundMemory deficits associated with senescence: A neurophysiological and behavioral study in the rat.
Barnes, C. A. (1979) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0077579 · Cited by 2,088
Remembrance of places passed: Spatial memory in rats.
Olton, D. S., & Samuelson, R. J. (1976) · Journal of Experimental Psychology: Animal Behavior Processes · doi:10.1037//0097-7403.2.2.97 · Cited by 1,998
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990 · cited 1×
“…politicization of AD, which has tended to confuse the guidelines for the diagnosis and treatment of a disease that is increasingly viewed as multifactorial and non-linear in both causality and progression (De Strooper & Karran, 2016; Medina, Khacha-turian, Rossor, Avila, & Cedazo-Minguez, 2017).”
BackgroundDominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau3333 · Cited by 1,966
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Mucke, L., Masliah, E., Yu, G.-Q., Mallory, M., Rockenstein, E. M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K., & McConlogue, L. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04050.2000 · Cited by 1,856
Policy: NIH to balance sex in cell and animal studies
Clayton, J. A., & Collins, F. S. (2014) · Nature · doi:10.1038/509282a · Cited by 1,816 · cited 1×
“…be resolved as the result of the NIH initiative to “monitor compliance of sex and gender inclusion in preclinical research funded by the agency” (Clayton & Collins, 2014) such that the contributions of sex can be considered alongside genotype in considering the results generated from animal…”
BackgroundEnhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159
Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences
Mielke, M., Vemuri, P., & Rocca, W. (2014) · Clinical Epidemiology · doi:10.2147/clep.s37929 · Cited by 1,021
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Rescuing US biomedical research from its systemic flaws
Alberts, B., Kirschner, M. W., Tilghman, S., & Varmus, H. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404402111 · Cited by 817
Alzheimer's disease: experimental models and reality
Drummond, E., & Wisniewski, T. (2017) · Acta Neuropathologica · doi:10.1007/s00401-016-1662-x · Cited by 810 · cited 4×
“…modifications of A β in the transgenic models being different from those in the human (Morris et al., 2018), while others fail to demonstrate aspects of neuronal loss and dysfunction, including synaptic and axonal function (Drummond & Wisniewski, 2017; Onos, Sukoff Rizzo, Howell, & Sasner, 2016).”
BackgroundMethodInfluentialWebster, S. J., Bachstetter, A. D., Nelson, P. T., Schmitt, F. A., & Van Eldik, L. J. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00088 · Cited by 755 · cited 3×
“…in terms of genetics (Newman et al., 2017) or in terms of the onset, progression and duration, of the LOAD disease phenotype which is often non-physiological (Drummond & Wisniewski, 2017; Puzzo, Lee, Palmeri, Calabrese, & Arancio, 2014; Sabbagh, Kin-ney, & Cummings, 2013; Webster et al., 2014).”
BackgroundTREM2 — a key player in microglial biology and Alzheimer disease
Ulland, T. K., & Colonna, M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0072-1 · Cited by 735 · cited 1×
“While invoking a contribution from the innate immune sys-tem, the R47H variant of TREM-2 confers a loss-of-function that, while rare in AD, has been associated with a tripling of the risk for the disease (Ulland & Colonna, 2018; Ulrich, Ulland, Colonna, & Holtzman, 2017).”
BackgroundModes and models of forebrain cholinergic neuromodulation of cognition
Hasselmo, M. E., & Sarter, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.104 · Cited by 733
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms
Andorfer, C., Kress, Y., Espinoza, M., De Silva, R., Tucker, K. L., Barde, Y., Duff, K., & Davies, P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01879.x · Cited by 722
Ramsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702
Morgan, P., Van Der Graaf, P. H., Arrowsmith, J., Feltner, D. E., Drummond, K. S., Wegner, C. D., & Street, S. D. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.020 · Cited by 692
Preclinical research: Make mouse studies work
Perrin, S. (2014) · Nature · doi:10.1038/507423a · Cited by 668 · cited 5×
“…protein TDP43 and a defective version of the SOD1 gene (which is mutated in 10% of the familial ALS population) was associated with motor neuron loss, protein aggregation, and progressive muscle atrophy, but the progressive deterioration seen in the human disease did not occur (Perrin, 2014).”
BackgroundInfluentialFriedman, B. A., Srinivasan, K., Ayalon, G., Meilandt, W. J., Lin, H., Huntley, M. A., Cao, Y., Lee, S.-H., Haddick, P. C. G., Ngu, H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.066 · Cited by 662 · cited 1×
“The incorporation of models from other therapeutic areas that involve aspects of the human immune response (Tao and Reese, 2017; Friedman et al., 2018) or diabetes (Drucker, 2016), may lead to additional challenges in testing cognitive deficits.”
BackgroundAnimal models of human disease: challenges in enabling translation
McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610 · cited 3×
“The predictive value of animal models in the translational process in drug discovery has been the subject of active controversy for at least the past 20 years, irrespective of the therapeutic area (McGonigle & Ruggeri, 2014:”
BackgroundDesign, power, and interpretation of studies in the standard murine model of ALS
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701856300 · Cited by 504 · cited 1×
“…experimental design, limitations that coupled with “the high noise floor of the model . . . . support the conclusion that the bulk of published studies using the SOD1G93A mouse model may unfortunately be measurements of biological variability due to inappropriate study design” (Scott et al., 2008).”
BackgroundJonasson, Z. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.10.006 · Cited by 498 · cited 1×
“Similar controversies exist pre-clinically with reported sex differences in rat and mouse models of learning and memory (Jonasson, 2005), and in transgenic mice (Rae & Brown, 2015), where reports of females”
BackgroundTREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440 · cited 1×
“…Trem2, a cell-surface receptor which is present on microglia and regulates the innate immune system response to A β pathology (Ulrich et al., 2017; Yeh et al., 2017), the gene mutations in these models are almost exclusively focused on amyloid, and to a far lesser extent tau, the two hallmarks of…”
BackgroundThe amyloid hypothesis on trial
Makin, S. (2018) · Nature · doi:10.1038/d41586-018-05719-4 · Cited by 360
Animal models of aging research: implications for human aging and age-related diseases
Mitchell, S. J., Scheibye-Knudsen, M., Longo, D. L., & de Cabo, R. (2015) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110829 · Cited by 328
Elucidating the Role of TREM2 in Alzheimer’s Disease
Ulrich, J. D., Ulland, T. K., Colonna, M., & Holtzman, D. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.042 · Cited by 325
Evaluation of excess significance bias in animal studies of neurological diseases
Tsilidis, K. K., Panagiotou, O. A., Sena, E. S., Aretouli, E., Evangelou, E., Howells, D. W., Salman, R. A.-S., Macleod, M. R., & Ioannidis, J. P. A. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001609 · Cited by 295 · cited 2×
“Despite this, efficacy outcomes for new AD therapeutics are often reported as significant based on small effect sizes, minimal animal numbers that have not been repeated such that their value is overstated and questionable, reflecting reporting and significance bias (Tsilidis et al., 2013).”
BackgroundA Comprehensive Behavioral Test Battery to Assess Learning and Memory in 129S6/Tg2576 Mice
Wolf, A., Bauer, B., Abner, E. L., Ashkenazy-Frolinger, T., & Hartz, A. M. S. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147733 · Cited by 281 · cited 3×
“In a behavioral assessment of the 129S6/Tg2546 transgenic mouse, Wolf et al. (2016) used a battery of tests (Fig.”
MethodInfluentialUsing the mouse to model human disease: increasing validity and reproducibility
Justice, M. J., & Dhillon, P. (2016) · Disease Models & Mechanisms · doi:10.1242/dmm.024547 · Cited by 281
Rice, H. C., de Malmazet, D., Schreurs, A., Frere, S., Van Molle, I., Volkov, A. N., Creemers, E., Vertkin, I., Nys, J., Ranaivoson, F. M., et al. (2019) · Science · doi:10.1126/science.aao4827 · Cited by 281 · cited 1×
“APP-related peptide modulation of α 7 nAChR (Wang et al., 2009) and GABA B receptor activity (Rice et al., 2019) may also disrupt synaptic connectivity and neuronal function.”
BackgroundDistinguishing between exploratory and confirmatory preclinical research will improve translation
Kimmelman, J., Mogil, J. S., & Dirnagl, U. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001863 · Cited by 236 · cited 3×
“The design, conduct, analysis, and reporting of a therapeutic animal study should be analogous in rigor to that required for human clinical trials (Kimmelman, Mogil, & Dirnagl, 2014) and are distinct from an exploratory study and should be analyzed, interpreted, and reported as such.”
BackgroundResultInfluentialNeuronal nicotinic receptors: A perspective on two decades of drug discovery research
Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.033 · Cited by 208
Self-citationToward more predictive genetic mouse models of Alzheimer’s disease
Onos, K. D., Sukoff Rizzo, S. J., Howell, G. R., & Sasner, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.12.003 · Cited by 156
Gender Differences in Alzheimer Disease: Brain Atrophy, Histopathology Burden, and Cognition
Filon, J. R., Intorcia, A. J., Sue, L. I., Vazquez Arreola, E., Wilson, J., Davis, K. J., Sabbagh, M. N., Belden, C. M., Caselli, R. J., Adler, C. H., et al. (2016) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlw047 · Cited by 143 · cited 1×
“…that while the age of onset to dementia did not differ on the basis of gender, females, once they were diagnosed, were more likely to proceed to a severe pathological phenotype with a greater severity of neurofibrillary changes and changes in brain weight as compared to males (Filon et al., 2016).”
BackgroundNever waste a good crisis: confronting reproducibility in translational research
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.006 · Cited by 117 · cited 2×
“The incorporation of models from other therapeutic areas that involve aspects of the human immune response (Tao and Reese, 2017; Friedman et al., 2018) or diabetes (Drucker, 2016), may lead to additional challenges in testing cognitive deficits.”
BackgroundHargis, K. E., & Blalock, E. M. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.007 · Cited by 90 · cited 1×
“In this context, Hargis & Blalock (2017) re-ported a meta-analysis of 29 studies on brain transcriptional profiles from human, mouse, and rat animal models.”
MethodVoorhees, J. R., Remy, M. T., Cintrón-Pérez, C. J., El Rassi, E., Khan, M. Z., Dutca, L. M., Yin, T. C., McDaniel, L. N., Williams, N. S., Brat, D. J., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.023 · Cited by 78 · cited 2×
“…pathology, to show that any amyloid-associated disruptions in the blood brain barrier, synaptic connectivity, neuronal function, etc. do not impede the ability of a compound/biologic that is acting in an amyloid-independent manner, to improve cognitive or neuronal outcomes (Voorhees et al., 2018).”
BackgroundMethodMann, K. M. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh199 · Cited by 48
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Self-citation
Cited by
Poor Translatability of Biomedical Research Using Animals — A Narrative Review
Marshall, L. J., Bailey, J., Cassotta, M., Herrmann, K., & Pistollato, F. (2023) · Alternatives to Laboratory Animals · doi:10.1177/02611929231157756 · Cited by 219
Granzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
Stazi, M., & Wirths, O. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02120-z · Cited by 59
Carter, C. S., Richardson, A., Huffman, D. M., & Austad, S. (2020) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glz298 · Cited by 51
Stefanescu, R., Stanciu, G. D., Luca, A., Paduraru, L., & Tamba, B.-I. (2020) · Biomolecules · doi:10.3390/biom10060870 · Cited by 35
Metadata
- Authors
- Mullane, K., & Williams, M.
- Venue
- Current Protocols in Pharmacology
- Publisher
- Wiley
- Published
- 2019-02-25
- Volume
- 84
- Issue
- 1
- Pages
- e57-e57
- ISSN
- 1934-8282 (ISSN-L)
- 1934-8290
- OpenAlex
- W2917810483
- Cited by
- 127
- References
- 55
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.